The short version of NR1D1 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-09. Anything still debated is marked as such rather than presented as settled.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
== Potential uses == Lobeline has been sold, in tablet form, for use as a smoking cessation aid, but scientific research has not provided supporting evidence for this use. Lobeline has also been studied for the treatment of other drug addictions such as addiction to amphetamines, cocaine, or alcohol; however, there is limited clinical evidence of any efficacy.
Angiotensin-converting-enzyme inhibitors (ACE inhibitors) are a class of medication used primarily for the treatment of cardiovascular and kidney diseases. This class of medicine works by causing relaxation of blood vessels as well as a decrease in blood volume, which leads to lower blood pressure and decreased oxygen demand from the heart. ACE inhibitors inhibit the activity of angiotensin-converting enzyme, an important component of the renin–angiotensin system which converts angiotensin I to angiotensin II, and hydrolyzes bradykinin. Therefore, ACE inhibitors decrease the formation of angiotensin II, a vasoconstrictor, and increase the level of bradykinin, a peptide vasodilator. This combination is synergistic in lowering blood pressure. As a result of inhibiting the ACE enzyme in the bradykinin system, the ACE inhibitor drugs allow for increased levels of bradykinin which would normally be degraded. Bradykinin produces prostaglandin. This mechanism can explain the two most common side effects seen with ACE Inhibitors: angioedema and cough.
=== Strategies for toxicity prevention === Understanding the mechanisms behind the toxicity of gliotoxin can open new possibilities for the use of gliotoxin therapeutically or as a diagnostic test for some conditions. One potential strategy that has been explored to reduce the toxicity of the fungi that produce gliotoxin is to target the gli gene cluster that controls the expression of gliotoxin protein. The disulfide bridge of gliotoxin is crucial to its toxicity, so it is theorized that the tailoring of enzymes to prevent the disulfide bridge closure by interfering with GliT or by catalyzing another reaction to block the sulfur residues may be beneficial in reducing the toxicity of those fungi. Another potential strategy is the targeting of the transcriptional activator GliZ, as deletion of the GliZ resulted in abrogated gliotoxin biosynthesis. This leads to the possible targeting of GliZ itself rather than any gene-based methodology to prevent it from binding to the gli gene cluster and activate transcription of the genes required for gliotoxin biosynthesis. One possible strategy for disrupting the regulation of gliotoxin transport is depleting the amount of GipA in the cell. GipA is a transcriptional regulator for the expression of the GliA transporter protein, which is required for gliotoxin secretion. These biosynthetic strategies for reducing the toxicity of pathogenic fungal strains that produce gliotoxin are still in their early stages of exploration but could provide novel methodologies for the adoption of therapeutic uses for gliotoxin.
As mentioned above, in field-flow fractionation the field can be hydraulic (with a cross flow through a semi-permeable membrane as the accumulation wall), gravitational, centrifugal, thermal, electrical, or magnetic. In all cases, the separation mechanism is produced by differences in particle mobility under the forces of the field, in a stationary equilibrium with the forces of diffusion: The field induces a downward drift velocity and concentration towards the accumulation wall, the diffusion works against this concentration gradient. After a certain time (called relaxation time) the two forces equilibrate in a stationary equilibrium. This is best visualized as a particle cloud, with all components in constant motion, but with an exponential decrease of the average concentration going away from the accumulation wall up into the channel. The decrease of air pressure going up from sea level has the same exponential decrease which is described in the barometric formula. After relaxation has been achieved, elution starts as the channel flow is activated. In the thin channel (typical height 250 to 350 μm) a parabolic laminar-flow-velocity profile exists, which is characterized by a strong increase of the flow velocity with increasing distance from the accumulation wall. This determines the velocity of a particular particle, based on its equilibrium position from the wall of the channel. Particles closer to the accumulation wall will migrate slower compared to others being higher up.
Glial cells are the supporting cells of the neurons. The three types of glial cells are astrocytes, oligodendrocytes, and ependymal cells, known collectively as macroglia, and the smaller scavenger cells known as microglia. Glial stem cells are found in all parts of the adult brain. Glial cells greatly outnumber neurons and apart from their supporting role to neurons, glia – astrocytes in particular have been acknowledged as being able to communicate with neurons involving a signalling process similar to neurotransmission called gliotransmission. They cannot produce an action potential as generated by a neuron but in their large numbers they can produce chemicals expressing excitability that exert an influence on neural circuitry. The star-like shape of the astrocyte allows contact with a great many synapses. Microglia account for about around 5–10% of cells found within the brain.
Sources: en.wikipedia.org
3 NH4SCN → 2 CH5N3 + H2S + CS2 The commercial route involves a two step process starting with the reaction of dicyandiamide with ammonium salts. Via the intermediacy of biguanidine, this ammonolysis step affords salts of the guanidinium cation (see below). In the second step, the salt is treated with base, such as sodium methoxide. Isothiouronium salts (S-alkylated thioureas) react with amines to give guanidinium salts:
In 2019, the Parliament of Togo approved a new bill that allowed Gnassingbé to stay in office until 2030. Despite that, many protests took place in the streets calling for the end of the dynasty after ruling at the time for 52 years.
Vitamin K is absorbed along with dietary fat from the small intestine and transported by chylomicrons in the circulation. Most of vitamin K1 is carried by triacylglycerol-rich lipoproteins (TRL) and rapidly cleared by the liver; only a small amount is released into the circulation and carried by LDL-C and HDL-C. MK-4 is carried by the same lipoproteins (TRL, LDL-C, and HDL-C) and cleared fast as well. The long-chain menaquinones are absorbed in the same way as vitamin K1 and MK-4 but are efficiently redistributed by the liver in predominantly LDL-C (VLDL-C). Since LDL-C has a long half-life in the circulation, these menaquinones can circulate for extended times resulting in higher bioavailability for extra-hepatic tissues as compared to vitamin K1 and MK-4. Accumulation of vitamin K in extra-hepatic tissues has direct relevance to vitamin K functions not related to hemostasis.
== Discovery == URP was discovered in rats when researchers were trying to locate urotensin II (UII), a neuropeptide that is a potent vasoconstrictor and increases REM cycles in the brain. The researchers designed antibodies using Goby UII as an antigen that would target the specific peptide sequence CFWKYC. When the peptide was observed using a mass spectrometer the scientists discovered this peptide was smaller than UII but had similar characteristics as well which is why it was called Urotensin II-related peptide.
==== Respiratory system ==== The respiratory system allows for gas exchange, particularly of carbon dioxide and oxygen, in human beings. In the process of breathing or ventilation, the muscles of respiration pump air into the lungs, bringing it into close contact with the blood via millions of microscopic air sacs known as alveoli. The upper respiratory tract includes the nose, nasal cavities, sinuses, pharynx and the part of the larynx above the vocal folds; the lower tract includes the lower part of the larynx and the following aiways: the trachea, bronchi, bronchioles and alveoli. The lungs are surrounded by flattened closed sacs known as pleura.
Sources: en.wikipedia.org
Carbon dioxide is gaining popularity among coffee manufacturers looking to move away from classic decaffeinating solvents. sCO2 is forced through green coffee beans which are then sprayed with water at high pressure to remove the caffeine. The caffeine can then be isolated for resale (e.g., to pharmaceutical or beverage manufacturers) by passing the water through activated charcoal filters or by distillation, crystallization or reverse osmosis. Supercritical carbon dioxide is used to remove organochloride pesticides and metals from agricultural crops without adulterating the desired constituents from plant matter in the herbal supplement industry. Supercritical carbon dioxide can be used as a solvent in dry cleaning. Supercritical carbon dioxide is used as the extraction solvent for creation of essential oils and other herbal distillates. Its main advantages over solvents such as hexane and acetone in this process are that it is non-flammable and does not leave toxic residue. Furthermore, separation of the reaction components from the starting material is much simpler than with traditional organic solvents. The CO2 can evaporate into the air or be recycled by condensation into a recovery vessel. Its advantage over steam distillation is that it operates at a lower temperature, which can separate the plant waxes from the oils. In laboratories, sCO2 is used as an extraction solvent, for example for determining total recoverable hydrocarbons from soils, sediments, fly-ash, and other media, and determination of polycyclic aromatic hydrocarbons in soil and solid wastes.
== Treatment == In May 2023, the US Food and Drug Administration (FDA) approved Vyjuvek for the treatment of wounds in people with dystrophic epidermolysis bullosa with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
=== Bone Marrow === Bone marrow can be used for testing but that depends on the quality and availability of the bones. So far there is no proof that says that certain bones are better than others when it comes to testing. Extracting bone marrow from larger bones is easier than smaller bones. Forensic toxicologists often use bone marrow to find what type poisons used, which can include cocaine or ethanol. Ethanol specifically is one of the most abused drugs worldwide, be it through alcohol consumption and abuse being a leading cause in death. Suicides, car crashes, and a variety of crimes are often performed under severe alcohol influence. The process of ethanol determination allows forensic toxicologists to utilize bone marrow post-mortem and isolate the ethanol level a person had been, and the metabolic speed of breakdown at which can be traced back to time of death.
There are also a few thousand Druze immigrants from Lebanon in the United States of America, who have converted to Christianity. In the period of Egyptian rule in the Levant in the 1830s, many Druze converted to Christianity to avoid enlistment into the Egyptian army. The baptism of children in accordance with Christian custom was usual in large, well-known Lebanese Druze families, according to historian Aharon Layish there is also explicit evidence of Druzes in Lebanon under the Ottoman rule were posing Christians for practical reasons. The early Druze migrants from Levant to Venezuela tended to mix well with the local population, and some Druze converted to Catholicism. By one estimate made by Elisabe Granli from University of Oslo, around 1,920 Syrian Druze converted to Christianity; according to the same study, Christians with a Druze background (Druze converts to Christianity) still regard themselves as Druze, and claim that there is no contradiction between being Druze and being Christian. According to the Druze religious courts, between 1952 and 2009, around 10% of Israeli Druze who left the Druze faith converted to Christianity. According to Open Doors, there is a small but growing community of Druze converts to Christianity in Syria and Lebanon, with most converting to Evangelical Protestantism. These converts have established churches specifically for Christians of Druze background, primarily comprising women, girls, and young men who have abandoned the Druze religion they were raised in.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.